These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 3710632)
1. Study of bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms as assessed by salivary data: Part II. Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I Int J Clin Pharmacol Ther Toxicol; 1986 Apr; 24(4):196-201. PubMed ID: 3710632 [TBL] [Abstract][Full Text] [Related]
2. Effect of food on bioavailability and pharmacokinetics of theophylline following administration of two sustained release dosage forms: Part I. Ohmori N; Inotsume N; Matsukura M; Higashi A; Iwaoku R; Tobino Y; Nakano M; Matsuda I Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):148-52. PubMed ID: 3699941 [TBL] [Abstract][Full Text] [Related]
3. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA; Straughan AB Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239 [TBL] [Abstract][Full Text] [Related]
4. [Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state]. Bochsler HP; Meyer UA Schweiz Med Wochenschr; 1982 Nov; 112(47):1702-10. PubMed ID: 7178872 [TBL] [Abstract][Full Text] [Related]
5. Absorption of theophylline from conventional and sustained-release tablets. Fagerström PO; Mellstrand T; Svedmyr N Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455 [TBL] [Abstract][Full Text] [Related]
6. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses. Schuppan D; Molz KH; Staib AH; Rietbrock N Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis. Valet SB; Schwartz RH; Brooks JG Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982 [TBL] [Abstract][Full Text] [Related]
8. Absorption of sustained-release theophylline tablets. Fagerström PO; Heintz L Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207 [TBL] [Abstract][Full Text] [Related]
9. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur. Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057 [TBL] [Abstract][Full Text] [Related]
10. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels. Steinijans VW; Zech K; Fischer R Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100 [TBL] [Abstract][Full Text] [Related]
11. Absorption of theophylline from conventional and sustained-release tablets. Mellstrand T; Svedmyr N; Fagerström PO Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088 [TBL] [Abstract][Full Text] [Related]
12. Bioavailability of sustained-release theophylline formulations. Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of a new sustained-release theophylline preparation. Dahlqvist R; Billing B Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (350 mg Theograd, 350 mg Theolair Retard and 300 mg Theodur) in steady state in healthy volunteers and asthmatics--Part I: Theophylline plasma levels. van der Vet AP; Drost RH; Kreukniet J; Maes RA Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):423-9. PubMed ID: 6490224 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of a short- and long-acting theophylline medication (theolair and Theolair retard) in normals and asthmatics. Part I: pharmacokinetics. Utama I; Kreukniet J; Meering PG; Maes RA Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):287-91. PubMed ID: 6885202 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147 [TBL] [Abstract][Full Text] [Related]
17. A comparison of the plasma profiles of two slow-release theophylline preparations (Nuelin depot and Theo-dur) in healthy volunteers. Talseth T; Boye NP; Bredesen JE; Kornstad S Ann Allergy; 1981 May; 46(5):279-80. PubMed ID: 7235323 [TBL] [Abstract][Full Text] [Related]
18. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)]. Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962 [TBL] [Abstract][Full Text] [Related]
19. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets. Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770 [TBL] [Abstract][Full Text] [Related]
20. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects. Bialer M; Salame K; Raz I Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):662-7. PubMed ID: 4093206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]